Key result
Palonosetron and Ramosetron reduced the incidence of postoperative nausea and vomiting at 2 hours compared to normal saline in high-risk women undergoing laparoscopic gynecological procedures.
Why the study?
The study aimed to evaluate the efficacy of Ramosetron and Palonosetron in preventing post-operative nausea and vomiting in high-risk patients.
Does palonosetron or ramosetron reduce the incidence of post-operative nausea and vomiting in high-risk female patients undergoing laparoscopic gynecological procedures compared to placebo?
RCT (n=81)
Double-blind
Randomized
No
Does palonosetron or ramosetron reduce the incidence of post-operative nausea and vomiting in high-risk female patients undergoing laparoscopic gynecological procedures compared to placebo?
Palonosetron and ramosetron are equally effective in reducing the incidence of early postoperative nausea compared to placebo in high-risk women undergoing laparoscopic gynecological surgery.
Answers are grounded in this paper and cite their sources.
Validates either 5-HT3 antagonist as an effective prophylactic option for early postoperative nausea; extends.
Objectives: In this study we aim to study the efficacy of Ramosetron and Palonosetron in preventing post-operative nausea and vomiting in high risk patients. Study Design: A randomized controlled trial. Setting: A Large Tertiary Care Centre in Karachi. Period: 9 months from January 2017 to September 2017. Method: N=81 participants took part in the study. The patient population was divided into three groups.. Patients belonging to group A received Palonosetron 0.075mg mixed with normal saline in a mixture of 3ml, prior to induction, and received 3ml of normal saline half an hour prior to the end of the procedure. Patients in group B received 3ml of normal saline prior to induction and a mixture of 0.3mg of Ramosetron mixed with normal saline as 3ml half an hour before end of procedure. In group C patients received normal saline 3ml both before induction and half an hour prior to end of surgery. Results: The patient demographics were similar in all the groups and no significant difference was found. The incidence of post-operative nausea and vomiting during 2 hours post operatively was 41.97%, the incidence of nausea at 2 hours was in group A= 33.33%, in group B= 29.62%, in group C= 62.96% respectively, having a p value of 0.014 refer to table 2. After 48 hours of surgery the overall incidence of vomiting in the groups was not significant having a p value of 0.428 and an incidence of 6.172%. Conclusion: Palonosetron and Ramosetron are equally effective in prevention of post-operative nausea and vomiting in high risk patients undergoing laparoscopic gynecological procedures.
No takes yet. Share an insight, caveat, or question.
Siddiqui et al. (2019) conducted an RCT in Postoperative nausea and vomiting (PONV) (n=81). Palonosetron and Ramosetron vs. Normal saline was evaluated on Incidence of postoperative nausea and vomiting at 120 minutes (p=0.014). Palonosetron and Ramosetron reduced the incidence of postoperative nausea and vomiting at 2 hours compared to normal saline in high-risk women undergoing laparoscopic gynecological procedures.
Synapse has enriched 10 related papers. Consider them for comparative context: